Aeterna Zentaris Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aeterna Zentaris Inc.
Private Company Edition: The global accelerator has new commitments from HHS and the Wellcome Trust. Also, Apollo buys into Sofinnova Partners with an up to €1bn investment, Castle Creek raised $124.6m in private funding this year in lieu of an IPO and Remix closed a $70m series B round.
Committee Chair Maria Cantwell (D-Wash.) solicits advice from witnesses for additional authorities to conduct oversight of PBMs and pushes for a GAO study.
ANDA sponsors say eliminating the HFC propellant, while important to help address climate change, could upend the generic market without guidance from the US FDA.
The company’s Phase I study of FHD-286 had a patient death due to differentiation syndrome, but that’s a known adverse event in multiple approved AML drugs.
- Specialty Pharmaceuticals
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing